Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[11C]CHDI-00485626 is a Carbon-11 labeled radiopharmaceutical developed as a Positron Emission Tomography (PET) imaging agent. It is designed to selectively bind to mutant huntingtin (mHTT) protein aggregates in the brain. Huntington's disease is characterized by the expansion of CAG repeats in the HTT gene, leading to the production of mHTT, which aggregates and causes neurodegeneration. This tracer allows for the non-invasive quantification of mHTT load in vivo, serving as a critical biomarker for disease progression and the evaluation of huntingtin-lowering therapies in clinical trials. It was developed through a collaboration involving the CHDI Foundation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [11C]CHDI-00485626.